Hancock Whitney Corp Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Hancock Whitney Corp boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 0.7% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 109,791 shares of the medical device company’s stock after acquiring an additional 785 shares during the quarter. Hancock Whitney Corp’s holdings in DexCom were worth $12,448,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Crewe Advisors LLC bought a new position in shares of DexCom in the first quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom in the 2nd quarter worth $25,000. DSM Capital Partners LLC bought a new position in shares of DexCom in the 4th quarter worth $28,000. Riverview Trust Co purchased a new stake in shares of DexCom during the 1st quarter valued at $32,000. Finally, Sachetta LLC lifted its holdings in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,483 shares of company stock worth $201,708. 0.30% of the stock is currently owned by corporate insiders.

DexCom Trading Down 2.1 %

DXCM opened at $70.43 on Friday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The business has a 50 day simple moving average of $78.19 and a two-hundred day simple moving average of $109.63. The firm has a market capitalization of $28.01 billion, a price-to-earnings ratio of 45.44, a PEG ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.34 earnings per share. Analysts predict that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Ratings Changes

DXCM has been the topic of a number of research reports. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Morgan Stanley decreased their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Wells Fargo & Company cut their target price on DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Barclays reduced their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Finally, Robert W. Baird upped their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.